Alcon stock

ALC · SIX · CHF

CHF 62.50Change from previous close: +1.86%Absolute change: +CHF 1.14

Close · November 16, 2026

Price history

+1.79% over the period

1 year: from CHF 61.40 (November 17, 2025) to CHF 62.50 (November 16, 2026), +1.79%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026CHF 62.50
October 30, 2026CHF 59.10
September 30, 2026CHF 53.98
August 31, 2026CHF 58.56
July 31, 2026CHF 55.38
June 30, 2026CHF 54.60
May 29, 2026CHF 52.10
April 30, 2026CHF 58.22
March 31, 2026CHF 59.26
February 27, 2026CHF 66.86
January 30, 2026CHF 62.42
December 30, 2025CHF 63.28
November 28, 2025CHF 63.86
November 17, 2025CHF 61.40

At a glance

  • The company

    Develops and sells eye care products for surgery and vision care, including intraocular lenses, contact lenses and ocular health products

  • Latest results

    Quarter to September 30, 2026 · EPS $0.91 (estimate $0.88)

TickerLandia's take on Alcon

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 47.80
52-wk highCHF 68.34

−8.55% from the 52-week high

Analysts · 27 analysts

Average targetCHF 73.98+18.37% vs. price

Buy 20 · Hold 6 · Sell 1 · Buy

TickerLandia Fingerprint: Alcon

Compared with similar companies: low dividend, high financial strength, and low profitability.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Alcon is pricier than similar companies

Alcon's P/E (trailing 12 months): 56.3, +34% against the median of a group of 10 similar companies (41.9).

Compared with 10 similar companies

Alcon's metrics compared with similar companies
MetricAlconPosition in the groupBand
P/E (trailing 12 months)56.3High
Forward P/E17.0Low
Operating margin12.9%Low
ROE3.0%Low
Debt/equity0.25Low

Grey band: the middle half of the group; tick: the median; dot: Alcon. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$2.74B

Latest quarter · Q3 2026

Net income

$260M

Latest quarter · Q3 2026

Quarterly net margin

9.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
CHF 29.48B
P/E
56.3
EPS
CHF 1.09
Volume
1.15M
Daily trading
€73.85M
Dividend yield
0.45%
Last ex-dividend on May 5, 2026

How Alcon is changing

All results
  • Revenue grew 8.8% a year on average over the last 5 years

  • Operating margin rose from 7.7% to 13.1%

  • Profits turn into cash: free cash flow equal to 137% of net income

Returns

Alcon returns with dividends

CHF 1,000 invested in Alcon 5 years ago, on November 16, 2021, would be worth CHF 826 today with dividends reinvested: −17.43% in total, −3.76% per year. On price alone it would be CHF 812 (−18.83%).

PeriodAlconSMICHF 1,000 becomes
1 month+14.18%+8.46%CHF 1,142
6 months+23.96%+14.27%CHF 1,240
Year to date−1.23%+13.86%CHF 988
1 year+2.28%+19.91%CHF 1,023
3 years+1.53%+41.93%CHF 1,015
5 years−17.43%+20.30%CHF 826

Over the last 6 months it has done better than 37% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Alcon: technical analysis

Alcon shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 26.2% below its all-time closing high (CHF 84.68, September 12, 2024).

Trend
No clear trend
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
+9.02%

Support and resistance

Price areas where Alcon has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. ResistanceCHF 65.71+5.13%3 touches, last on January 22, 2026
  2. ResistanceCHF 64.17+2.68%3 touches, last on November 5, 2026
  3. Last priceCHF 62.50
  4. SupportCHF 61.92−0.92%4 touches, last on August 11, 2026
  5. SupportCHF 59.62−4.61%2 touches, last on September 2, 2026
  6. SupportCHF 56.12−10.21%3 touches, last on July 3, 2026

Volatility and risk

Over the last year it has moved less than the SMI.

Beta (1 year) vs SMI
0.78
Volatility (60 sessions, annualised)
26.1%
Largest fall in the last year
−27.30%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Alcon: seasonality

Average monthly price change over 8 years

+2.3%Jan+2.4%Feb−2.6%Mar−1.2%Apr+1.8%May−0.4%Jun+2.3%Jul−1.1%Aug−3.4%Sep+0.0%Oct+2.0%Nov+1.0%Dec

Over the last 8 years, the strongest month for Alcon has been February: +2.38% on average, positive in 4 years out of 7. The weakest has been September: −3.39% on average, positive in 3 years out of 8. November, the current month, has been positive in 4 years out of 7 (+2.04% on average).

Show chart data
MonthAverageMedianPositive years
January+2.33%+3.91%4 of 7
February+2.38%+0.34%4 of 7
March−2.59%−0.22%3 of 7
April−1.22%−1.75%3 of 7
May+1.80%+0.68%4 of 8
June−0.43%+1.69%4 of 8
July+2.31%+1.66%6 of 8
August−1.09%−0.73%3 of 8
September−3.39%−3.76%3 of 8
October+0.02%−0.14%4 of 8
November+2.04%+1.70%4 of 7
December+1.02%−0.74%2 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Alcon and its competitors

With 25,000 employees, Alcon develops, makes and sells eye care products for surgery and daily vision. Its Surgical activities cover equipment, diagnostics and intraocular lenses, along with consumables for cataract and vitreoretinal procedures and refractive systems such as WaveLight. Its Vision Care activities include contact lenses and ocular health products for conditions such as dry eye, allergies and glaucoma, and the company is also developing encapsulated cell therapies for chronic eye diseases.

Headquarters
Geneva, Switzerland
Employees
25,000
Founded
1945
Chief executive
David Endicott
Alcon and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
AlconALC$35.16B12.9%56.3+23.96%
Sartorius Stedim BiotechDIM$24B19.2%67.0+44.71%
Straumann HoldingSTMN$20.43B24.7%46.5+30.89%
SartoriusSRT$19.89B17.8%79.3+38.35%
ColoplastCOLO.B$16.93B25.7%37.2+27.32%
EssilorLuxotticaEL$92.38B12.8%34.1+6.67%

Same industry or related industries, similar size. Compare Alcon with its competitors · Full profile